Altimmune, Inc.
ALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001326190
In the last 90 days, Altimmune, Inc. insiders filed 4 open-market purchases and 0 sales; 190 institutions reported holding it in 13F filings for Q3 2026, worth $407.4M in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 19, 2026
- $274.4M
- Insider buysLast 90 days, $96.4K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, −16 vs. previous quarter
- 190
- 13F valueReported value at the end of Q3 2026
- $407.4M
- Superinvestors holdingAt the end of Q3 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $41.0K
- +105.0% year over year
- Net income, FY2025
- -$88.1M
- No comparable prior period
- Free cash flow, FY2025
- -$67.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $88.1M (214861.0% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 42.1M
- Shares sold short
- Change
- −102.6K
- −0.2% vs. previous
- Days to cover
- 12.16
- At average daily volume
Superinvestors holding ALT, Q3 2026
Go to the superinvestors tab1 superinvestor reports holding Altimmune, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.1%
Altimmune, Inc.'s share of the portfolio
- Shares
- 6,700,000
- Value
- $19.2M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Altimmune, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)4:08 PM ET | Nov 18 | Same day | Menziuso Richard ThomasPrincipal Accounting Officer | PPurchaseCommon Stock, par value $0.0001 | +10.0K | $1.42 | +$14.2K | New position10.0K after | |
| Nov 13, 2026 (view filing)4:27 PM ET | Nov 13 | Same day | Weaver Gregory LChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 | +10.0K | $1.62 | +$16.2K | +15.9%73.0K after | |
| Nov 13, 2026 (view filing)4:27 PM ET | Nov 13 | Same day | Pisano WayneDirector | PPurchaseCommon Stock, par value $0.0001 | +10.0K | $1.64 | +$16.4K | +20.5%58.8K after | |
| Nov 13, 2026 (view filing)4:25 PM ET | Nov 13 | Same day | Durso Jerome BenedictPresident and CEO | PPurchaseCommon Stock, par value $0.0001 | +30.7K | $1.62 | +$49.7K | +49.1%93.2K after | |
| Aug 13, 2026 (view filing)4:05 PM ET | Aug 13 | Same day | Durso Jerome BenedictPresident and CEO | PPurchaseCommon Stock, par value $0.0001 | +15.0K | $2.95 | +$44.3K | +31.6%62.5K after | |
| Apr 6, 2026 (view filing) | Apr 6 | Same day | Gill JohnDirector | PPurchaseCommon Stock, par value $0.0001 | +9.20K | $3.41 | +$31.4K | +73.6%21.7K after | |
| Apr 1, 2026 (view filing) | Apr 1 | Same day | Durso Jerome BenedictPresident and CEO | PPurchaseCommon Stock, par value $0.0001 | +15.0K | $3.14 | +$47.1K | +46.2%47.5K after | |
| Apr 1, 2026 (view filing) | Apr 1 | Same day | Weaver Gregory LChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 | +10.0K | $3.15 | +$31.5K | +35.6%38.1K after | |
| Mar 9, 2026 (view filing) | Mar 6 | 3 days | Durso Jerome BenedictPresident and CEO | PPurchaseCommon Stock, par value $0.0001 | +20.0K | $3.54 | +$70.8K | +160.0%32.5K after | |
| Mar 9, 2026 (view filing) | Mar 6 | 3 days | Weaver Gregory LChief Financial Officer | PPurchaseCommon Stock, par value $0.0001 | +5.00K | $3.54 | +$17.7K | +21.7%28.1K after |
Top 10 13F holders, Q3 2026
See all 190 holdersThe largest institutional positions in Altimmune, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,960,259 | $59.9M | 0.00% | +574,975+2.8% | Added |
| Deep Track Capital, LP | 19,250,000 | $55.1M | 0.93% | 00.0% | Unchanged |
| State Street Corp | 8,356,408 | $23.9M | 0.00% | −3,742,132−30.9% | Reduced |
| Vanguard Portfolio Management LLC | 8,107,554 | $23.2M | 0.00% | +777,289+10.6% | Added |
| Vanguard Capital Management LLC | 7,812,919 | $22.3M | 0.00% | −364,833−4.5% | Reduced |
| Viking Global Investors LPSuperinvestorViking Global Investors | 6,700,000 | $19.2M | 0.06% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 6,500,000 | $18.6M | 0.19% | 00.0% | Unchanged |
| Marshall Wace, LLP | 5,431,302 | $15.5M | 0.01% | −1,409,753−20.6% | Reduced |
| Geode Capital Management, LLC | 4,884,491 | $14.0M | 0.00% | −126,823−2.5% | Reduced |
| Two Sigma Investments, LP | 4,241,069 | $12.1M | 0.01% | +1,859,927+78.1% | Added |
Holders of 5% or more of ALT
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Altimmune, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 13G | 9.99%19.4M shares | New | Apr 30, 20261 filing | Apr 30, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.60%6.13M shares | −1.10 ppfrom 8.70% | Feb 5, 20252 filings | Jul 16, 2025 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G | 6.70%13.4M shares | New | May 1, 20261 filing | May 1, 2026 | SEC |
| Ra Capital Management, L.P. | 13G | 6.50%13.0M shares | New | May 1, 20261 filing | May 1, 2026 | SEC |